

*8<sup>th</sup> Annual Angioma Alliance*  
**CCM SCIENTIFIC MEETING**

November 15-16, 2012

DoubleTree Bethesda – Washington, DC  
*Ballroom D*

**DAY 1 | THURSDAY, NOVEMBER 15<sup>TH</sup>**

---

7:45      **WELCOME & OPENING REMARKS**  
Amy Akers & Sara Sukalich – Angioma Alliance

**SESSION I – PROTEOMICS, STRUCTURE & FUNCTION**  
DOUG MARCHUK, SESSION CHAIR

8:00      ***New insights into the structure and function of CCM proteins***  
Titus Boggon – Yale University School of Medicine

8:20      ***Proteomics characterization of CCM complexes***  
Anne-Claude Gingras – Samuel Lunenfeld Research Institute

8:40      ***Structural Basis of the Junctional Anchorage of the Cerebral  
Cavernous Malformations Complex***  
Alexandre Gingras – University of California San Diego

**SESSION II – SIGNALING**  
BRENT DERRY, SESSION CHAIR

9:00      ***Defining the Ccm3 signaling pathway in a zebrafish model of CCM  
disease***  
Bilge Yoruk\*\* – Sick Kids Research Institute

9:20      ***CCM3 and senescence***  
Juan Zalvide – University of Santiago de Compostela

9:40      *COFFEE BREAK*

10:00     ***CCM3 functions in brain development***  
Angeliki Louvi – Yale School of Medicine

10:20     ***CCM3 regulates endosome recycling in the C. elegans excretory cell***  
Ben Lant – Sick Kids Research Institute

- 10:40 ***Novel Endothelial Signaling in CCM***  
Rebecca Stockton – University of California Los Angeles
- 11:00 ***Further Studies of Fasudil Treatment in Murine Models of Cerebral  
Cavernous Malformation Disease***  
Robert Shenkar – University of Chicago
- 11:20 DISCUSSION OF SESSIONS I & II
- 12:00 Lunch | Oz Restaurant

### **SESSION III – VASCULAR BIOLOGY & INFLAMMATION**

BRANT WEINSTEIN, SESSION CHAIR

- 1:00 ***The CCM2 paralogue CCM2L opposes canonical cerebral cavernous  
malformation signaling in endothelial cells during cardiovascular  
growth***  
Xiangjian Zheng – University of Pennsylvania
- 1:20 ***Loss of Notch signaling in the adult endothelium: implications for  
CCM***  
Andreas Fischer – German Cancer Research Center Heidelberg (DKFZ)
- 1:40 ***The recombinant antibody construction and restricted B cell  
repertoire in Human Cerebral Cavernous Malformation (CCM)***  
Changbin Shi – University of Chicago
- 2:00 ***Decreased KRIT1 expression leads to increased vascular  
permeability and modifies inflammatory responses in vivo.***  
Angela Glading – University of Rochester
- 2:20 ***CCM2 intersects a novel pathway of cytokine mediated vascular  
instability***  
Dean Li – University of Utah
- 2:40 *COFFEE BREAK*

### **SESSION IV – LESION GENESIS**

KEVIN WHITEHEAD, SESSION CHAIR

- 3:00 ***Novel insights into the relationship between KRIT1 and ROS  
homeostasis: KRIT1 loss-of-function causes a ROS-dependent  
upregulation of transcription factors involved in oxidative stress  
response***  
Saverio Francesco Retta – University of Torino

- 3:20 ***Exploring the Implications of a Two-Hit Mechanism in Cerebral Cavernous Malformations***  
David McDonald\*\* - Duke University Medical Center
- 3:40 ***CCM3-dependent EC-SMC/pericyte interactions in CCM lesion development mouse models and mechanistic studies***  
Wang Min – Yale University
- 4:00 ***Angiogenesis is Required for Cavernous Malformation Development***  
Kevin Whitehead – University of Utah
- 4:20 *DISCUSSION OF SESSIONS III & IV*
- 5:00 *END OF DAY 1*
- 7:00 DINNER | BALLROOM C

## **DAY 2 | Friday, November 16<sup>th</sup>**

---

- 8:30 **WELCOME**  
Connie Lee – Angioma Alliance & CCM<sub>3</sub> Action

### **SESSION V – MAGNETIC RESONANCE IMAGING TECHNOLOGIES**

*LESLIE MORRISON, SESSION CHAIR*

- 8:40 ***Quantitative Iron Burden as a Biomarker of Cumulative Hemorrhages in Cerebral Cavernous Malformations: Studies in Mouse and Man***  
Luying (Ryan) Li\*\* – West China Medical School of Sichuan University & University of Chicago
- 9:00 ***Novel Magnetic Resonance Imaging Biomarkers of Human CCM Disease: Dynamic Contrast-Enhanced Quantitative Perfusion***  
Abdul Ghani Mikati\*\* – University of Chicago
- 9:20 ***White Matter Hyperintensities in CHM CCM1***  
Blaine Hart – University of New Mexico
- 9:40 *COFFEE BREAK*

### **SESSION VI – CLINICAL STUDIES**

*ISSAM AWAD, SESSION CHAIR*

- 10:00 ***Spectrum of Human Causative Mutations in the KRIT1, CCM2 and PDCD10 Genes***  
James Weber – PreventionGenetics

- 10:20      ***Clinical Factors Associated with Lesion Count in Familial Cerebral Cavernous Malformation Type 1 Patients with the Common Hispanic Mutation***  
Hélène Choquet\*\* – University of California San Francisco
- 10:40      ***Cutaneous Features of the CCM1-CHM Cohort***  
Leslie Morrison – University of New Mexico
- 11:00      ***Outcome after surgical or conservative management of cerebral cavernous malformations: a prospective, population-based cohort study***  
Margaret A. Horne\*\* - University of Edinburgh
- 11:20      DISCUSSION OF SESSION V & VI
- 12:00      LUNCH | OZ RESTAURANT

**Session VII – Panel Discussion of Clinical Trails for CCM**

- 1:00      ***Biomarkers***  
Issam Awad – University of Chicago
- 1:10      ***Recruitment Strategies***  
Leslie Morrison – University of New Mexico
- 1:20      ***Trials & Research Consortia***  
William Young – University of California San Francisco
- 1:30      ***Food & Drug Administration Perspective***  
Gumei Liu – Rare Diseases Program Office of New Drugs
- 1:40      ***National Institutes of Health Perspective***  
Claudia Moy – NINDS office of Clinical Research
- 1:50      OPEN DISCUSSION
- 3:00      CLOSE OF MEETING

**MEETING SPONSORS**

**ANGIOMA ALLIANCE**

**NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS & STROKE**

**CCM3 ACTION**

**INNOLYST (PATIENT CROSSROADS)**

\*\*Trainee Travel Award Winner